Form 4: Xeris Biopharma Holdings Director John P. Schmid Reports Acquisition of 50,000 Shares

Director John P. Schmid reports acquiring 50,000 shares of Xeris Biopharma Holdings through a restricted stock unit award.

Summary

• On June 5, 2024, John P. Schmid, a director of Xeris Biopharma Holdings, Inc., acquired 50,000 shares of common stock through a restricted stock unit award.
• The shares were acquired at a price of $0.
• These shares will vest in full on June 5, 2025, or at the company's next annual meeting of stockholders, whichever comes first.
• Following the transaction, Schmid directly owns 113,159 shares of common stock and indirectly owns 16,400 shares through The Schmid Family Trust dated August 15, 2017.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by a director. The acquisition itself can be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units will vest on June 5, 2025, or at the company's next annual meeting of stockholders.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership changes of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates